Search results
GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology
Reuters via Yahoo Finance· 1 day ago(Reuters) -GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing...
Cancer breakthrough as scientists develop jab that could provide miracle cure
Daily Express· 1 day agoA revolutionary skin cancer vaccine being tested on British patients offers hope of a cure for the...
Pfizer vs Moderna battle over COVID vaccine patents begins in UK By Reuters
Investing.com· 4 days agoPfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) asked a London court to revoke rival Moderna...
BioNTech SE to Post Q1 2024 Earnings of $1.26 Per Share, HC Wainwright Forecasts (NASDAQ:BNTX)
ETF DAILY NEWS· 5 days agoBioNTech SE (NASDAQ:BNTX – Free Report) – Stock analysts at HC Wainwright issued their Q1 2024 earnings per share (EPS) estimates for shares of BioNTech ...
Moderna, Pfizer/BioNTech set for UK court clash over COVID jab patents
Medical Xpress· 4 days agoA row between pharmaceutical firms Moderna and Pfizer/BioNTech comes to court in London on Tuesday...
BioNTech SE (NASDAQ:BNTX) Position Reduced by Vontobel Holding Ltd.
ETF DAILY NEWS· 1 week agoVontobel Holding Ltd. trimmed its stake in shares of BioNTech SE (NASDAQ:BNTX – Free Report) by 33.7% during the fourth quarter, according to its most recent filing with the ...
Brokerages Set BioNTech SE (NASDAQ:BNTX) PT at $120.40
ETF DAILY NEWS· 1 week agoBioNTech SE (NASDAQ:BNTX – Get Free Report) has been assigned a consensus recommendation of “Hold” from the ten ratings firms that are currently covering the stock, Marketbeat ...
BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
Morningstar· 5 days agoBioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2024 on Monday, May 6, 2024. Additionally ...
HC Wainwright Reaffirms “Buy” Rating for BioNTech (NASDAQ:BNTX)
ETF DAILY NEWS· 1 week agoBioNTech (NASDAQ:BNTX – Get Free Report)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research note issued to investors on Wednesday, Benzinga reports ...
Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown -...
Benzinga· 3 days agoModerna Inc. MRNA is set to clash with Pfizer Inc. PFE and BioNTech SE BNTX in a pivotal London...